Pneumonia is a lung infection caused by bacteria or viruses. Infection of pneumonia occurred due to social contact is referred as community acquired pneumonia (CAP). Pathogens that cause community acquired pneumonia (CAP) are Haemophilus influenza, Streptococcus pneumonia, atypical bacteria namely Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella sp.
Browse the Complete Details of this Report at: http://www.transparencymarketresearch.com/community-acquired-pneumonia-market.html
Common symptoms of community acquired pneumonia include, cough, fever, chest pain, tachycardia, sudden loss of appetite, hypothermia, excessive fatigue, nausea, vomiting, migraine, blueness of skin, coughing up blood and rapid and painful breathing. Every year 4 million to 5 million new cases of community acquired pneumonia (CAP) are detected globally, out of which 25% of the cases require hospitalization. Based on the diagnosis type, the global community acquired pneumonia market is classified as follows:
> Laboratory Testing
> Blood Cultures
> Sputum Testing
> Urine Testing
> Pneumococcal Antigen Testing
> Creatine Phosphokinase (CPK) Levels
> Ferritin Levels
> C-reactive Protein (CRP) Levels
> Procalcitonin Levels
Based on the treatment, the global community acquired pneumonia market is segmented as follows:
> Pencillin G
Rising incidences of the disease worldwide coupled with increasing awareness about availability of disease related treatments are the major factors that are driving the global community acquired pneumonia market towards growth. While on the other hand, rising drug resistance among disease causing pathogens is one of the major factors restraining the growth of the global community acquired pneumonia (CAP) market.
Geographically, the global community acquired pneumonia (CAP) market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). North America comprises community acquired pneumonia (CAP) market for the U.S and Canada. Europe comprises cumulative market of community acquired pneumonia (CAP) in Germany, Italy, France, Spain, and Rest of Europe (RoE). Asia Pacific comprises cumulative market of community acquired pneumonia (CAP) in China, India, Australia, New Zealand and rest of Asia Pacific (RoAPAC). Rest of the World (RoW) comprises community acquired pneumonia (CAP) market in Latin America, Middle East and Russia. Europe and North America are dominating the global community acquired pneumonia (CAP) market. Highly developed healthcare infrastructure, high awareness about availability of diagnostic tests and treatment therapies coupled with presence of well structured regulatory framework are some of the factors that are driving the Europe and North American community acquired pneumonia market. Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period from 2014 to 2020. Rapidly improving healthcare infrastructure on the grounds of booming medical tourism industry in this region is the prime driver for growth of the community acquired pneumonia (CAP) market in Asia Pacific. In addition, swiftly rising disposable income, coupled with availability of government funds to improve healthcare facilities in the region are some other factors that are fueling the growth of the community acquired pneumonia (CAP) market in Asia Pacific region. India, Japan, China, and South Korea are the fastest growing markets in Asia Pacific region. Moreover, Argentina, Mexico and Brazil are the countries in Rest of the World (RoW) region that are expected to show faster growth in this region.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453